Pierre SOUBEYRAN

Adresse professionnelle : Institut Bergonié – Centre Régional de Lutte contre le Cancer 229 cours de l’Argonne – CS 61283
33076 Bordeaux Cedex, France
Tel : 05 56 33 32 67
E-mail : p.soubeyran@bordeaux.unicancer.fr
Date de naissance : 16 février 1961

N° d’inscription à l’Ordre des Médecins : 33/09177 depuis le 01.10.92 section oncologie

SITUATION ACTUELLE

• Oncologue Médical (depuis 1993) / Institut Bergonié, Bordeaux
• Professeur des Universités – Praticien Hospitalier (depuis 2006) / Université de Bordeaux
• Directeur SIRIC BRIO (Bordeaux Recherche Intégrée Oncologie depuis 2013) Institut Bergonié, CHU et Université de Bordeaux
• Directeur de l’Unité INSERM U1218 ACTION (depuis 2015) / INSERM (Actions for Oncogenesis understanding and Target Identification in Oncology)
• Directeur de la Recherche (depuis mai 2016) / Institut Bergonié, Bordeaux

TITRES HOSPITALO-UNIVERSITAIRES   

ÉTUDES MÉDICALES (1978 à 1984) / Université de Nantes

ETUDES DE SPÉCIALITÉ

• Interne des Hôpitaux de Bordeaux (1984 à 1988) / Institut Bergonié et CHU de Bordeaux
• Chef de clinique Assistant – Bordeaux (1989 à 1992) /  Université de Bordeaux
  • Service d’Oncologie Médicale du Pr Hœrni (novembre 1989 à novembre 1992). Institut Bergonié
  • Project Investigator – Hematopathology Program, Dept. of Lab. Medicine MD Anderson Cancer Center (novembre 1990 – novembre 1991) Houston, TX, USA (mis en position de délégation par les Ministères de la Santé et de l’Education Nationale)
• Médecin spécialiste des CLCC (1993 2006) / Institut Bergonié
• Coordonnateur du Groupe Hématologie de l’Institut Bergonié (2005-2014) / Institut Bergonié
• Coordonnateur de la Recherche Clinique de l’Institut Bergonié (2002-2011) / Institut Bergonié
  Professeur des Universités – Praticien Hospitalier (2006) / Université de Bordeaux

TITRES UNIVERSITAIRES

• Thèse de Médecine (1989) / Université de Bordeaux
  Lymphomes Folliculaires. Analyse d’une série de 281 patients.
• Mémoire de DES de Radiothérapie (1989) / Université de Bordeaux
  Complications rectales des cancers du col utérin traités par association de radiothérapie externe et de curiethérapie. Analyse des facteurs conditionnant leur survenue.
• Diplôme d’Études Approfondies de Biologie Santé (1990) / Université de Bordeaux
  Option Expression et régulation chez les eucaryotes
• DESC de Cancérologie (1991) / Université de Bordeaux
• Qualification en Oncologie Médicale (1993)  Ordre National des Médecins
• Thèse pour le Doctorat de l’Université de Bordeaux 2 (1996) / Université de Bordeaux / Mention : Sciences Biologiques et Médicales – Option : Biologie-Santé                                               
• Habilitation à Diriger des Recherches (2001) / Université de Bordeaux

DISTINCTIONS

• Prix de Thèse de Cancérologie de l’Université de Bordeaux 2 et de la Ligue Nationale contre le Cancer, 1997.
• BJ Kennedy Award for the best poster presentation: Prognostic factors of functional decline in elderly cancer patients receiving first-line chemotherapy. International Society of Geriatric Oncology (SIOG), Paris, November 2011.
• Paul Calabresi Memorial Lecture Award: From suboptimal to optimal treatment in older patients with cancer. International Society of Geriatric Oncology (SIOG), Manchester, October 2012.
• BJ Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology: Improving older cancer patients’ treatment: hope for the future. 52^nd ASCO Annual Meeting 2016. Chicago, June 3-7, 2016.
• Ehrenpreis Geriatrische Onkologie für das Lebenswerk 2017: Development of Geriatric Oncology in France. German Society of Hematology and Oncology (DGHO) and German Society of Geriatrics (DGG), Stuttgart (Germany), September 2017

Publications sélectionnées des cinq dernières années dans des revues à comité de lecture

1. Soubeyran P, Henriques de Figueredo B, Soubeyran I, Mertens C, Cazeau AL. Therapeutic strategies in elderly and very elderly patients. Best Practice & Research Clinical Haematology 2012; 25(1): 91-100. doi: 10.1016/j.beha.2012.01.009 (IF 2011: 2,637)
2. Soubeyran P, Fonck M, Rainfray M, Blanc-Bisson C, Mertens C, Imbert Y, Cany L, Vogt L, Dauba J, Palis R, Andriamampionona F, Houédé N, Floquet A, Chomy F, Brouste V, Ravaud A, Bellera C and Rainfray M. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012; 30(15): 1829-34 (IF 2011: 18,372)
3. Wildiers H, Brain E, Penninckx B, Ring A, Repetto L, Soubeyran P, Monfardini S, Aapro M, Wedding U. The EORTC Cancer in the Elderly Task Force, a protostar for EORTC’s future. Eur J Cancer Supplements 2012; 10(1): 34-38 (IF 2011: 5,536)
4. Bellera CA, Rainfray M, Mathoulin-Pélissier S, C Mertens, F Delva, Fonck M, Soubeyran P. Towards a screening tool in geriatric oncology: methodological and clinical considerations of the G8 screening tool. Ann Oncol 2012, 23(8): 2166-72 doi: 10.1093/annonc/mdr587 (IF 2011: 6,425)
5. Delva F, Soubeyran P, Rainfray M, Mathoulin-Pélissier S. Referral of elderly cancer patients to specialists: action proposals for general practitioners. Cancer Treat Rev 2012 Nov;38(7):935-41 (IF 2011: 6,054)
6. Soubeyran P, Brouste V, Bellera C and Rainfray M. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. Reply to Lagro. J Clin Oncol 2012; 30 (35): 4443-5 (IF 2011: 18,372)
7. Mathoulin-Pélissier S, Bellera C, Rainfray M, Soubeyran P. Strategies for determining the best geriatric screening method for frailty. Lancet Oncol 2013, 14 (1): e1-2 doi: 10.1016/S1470-2045(12)70554-5 (IF 2011: 22,589)
8. Allart P, Cousson-Gélie F, Soubeyran P. Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature. PsychoOncology 2013, 22 (2): 241-9 doi: 10.1002/pon.3026 (IF 2011: 3,339)
9. Abraham I, MacDonald K, Tharmarajahb S, Bokemeyer C, Ludwig H, Soubeyran P, Battistel V, Aapro M. Modeling of treatment response to erythropoiesis-stimulating agents in older (age ≥70 years) and younger (age<70 years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study. J Ger Oncol 2013 (4): 196-201 (IF 2011: 1)
10. Carine Bellera, Delphine Praud, Aurélie Petit-Monéger, Pippa McKelvie-Sebileau, Pierre Soubeyran, Simone Mathoulin-Pélissier. Barriers to inclusion of older adults in randomised clinical trials on Non-Hodgkin’s Lymphoma: A systematic review. Cancer Treat Rev 2013; 39(7): 212-7. doi:pii: S0305-7372(13)00017-0. 10.1016/j.ctrv.2013.01.007. (IF 2011: 6,054)
11. Soubeyran P. From suboptimal to optimal treatment in older patients with cancer. J Ger Oncol 2013, 4: 291-3, http://dx.doi.org/10.1016/j.jgo.2013.04.007
12. Hoppe S, Rainfray M, Fonck M, Hoppenreys L, Blanc JF, Ceccaldi J, Mertens C, Blanc-Bisson C, Imbert Y, Cany L, Vogt L, Dauba J, Houédé N, Bellera C, Floquet A, Fabry MN, Ravaud A, Chakiba C, Mathoulin-Pélissier S, Soubeyran P. Prognostic factors of functional decline in elderly cancer patients receiving first-line chemotherapy. J Clin Oncol 2013; 31(31): 3877-82
13. Schmitt A, Soubeyran P. New drugs for follicular lymphoma in older adults. Anti-Cancer Agents Med Chem 2014, Jun;14(5):657-64 (IF 2011: 2,862)
14. Bourdel-Marchasson I, Blanc-Bisson C, Doussau A, Germain C, Blanc JF, Dauba J, Lahmar C, Terrebonne E, Lecaille C, Ceccaldi J, Cany L, Lavau-Denes S, Houede N, Chomy F, Durrieu J, Soubeyran P, Senesse P, Chene G, Fonck M. Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: A two-year randomized controlled trial. Plos One 2014; 9 (9): e108687. doi: 10.1371/journal.pone.0108687
15. Falandry C, Krakowski I, Curé H, Carola E, Soubeyran P, Guérin O, Freyer G. Granulocyte-Colony-Stimulating-Factor in Elderly Patients Receiving Chemotherapy for Breast and Gynaecological Cancers: Results of a French Survey. AntiCancer Res 2014; 2014 Sep;34(9):5007-15.
16. Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, Albrand G, Servent V, St Jean O, van Pragh I, Kurtz JE, Périn S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Droz JP, Mathoulin-Pélissier S, Rainfray M, for the ONCODAGE investigators. Screening for vulnerability in elderly cancer patients: Validation of the G8 screening test. Plos One 2014 ; 9(12): e115060. doi: 10.1371/journal.pone.0115060
17. Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman S. Diffuse large B-cell lymphoma in the elderly : Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology Expert Position Paper. J Ger Oncol 2015; 6(2):141-52. doi: 10.1016/j.jgo.2014.11.004
18. Terret C, Albrand G, Rainfray M, Soubeyran P. Impact of comorbidities on the treatment of non-Hodgkin’s lymphoma: a systematic review. Expert Rev Hematol 2015; 8(3):329-41.
19. Morrison V.A., Hamlin P., Soubeyran P., Stauder R., Wadhwa P., Aapro M., Lichtman S.M.. Approach to therapy of Diffuse Large B-Cell Lymphoma in the Elderly: The International Society of Geriatric Oncology (SIOG) Expert Position Commentary. Ann Oncol 2015 ; 26(6) : 1058-68
20. Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Barrié M, Sierra del Rio M, Gonzalez-Aguilar A, Houllier C, Delgadillo D, Lacomblez L, Tanguy ML and Hoang Xuan K. Methotrexate and Temozolomide (MT) versus Methotrexate, Procarbazine, Vincristine and Cytarabine (MPV-A) for Primary CNS Lymphoma in the Elderly: An Intergroup ANOCEF-GOELAMS Randomized Phase II Trial. Lancet Haematology 2015; 2(6): E251-9
21. Bourdel-Marchasson Isabelle, Diallo Abou, Bellera Carine, Blanc-Bisson Christelle, Durrieu Jessica, Germain Christine, Mathoulin-Pélissier Simone, Soubeyran Pierre, Rainfray Muriel, Fonck Marianne, Doussau Adelaïde. One-year mortality in older patients with cancer: development and external validation of an MNA-based prognostic model. PlosOne 2016;11(2):e0148523. doi: 10.1371/journal.pone.0148523. eCollection 2016
22. Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, Soubeyran P, Mathoulin-Pelissier S, Tournigand C, Paillaud E, Laurent M, Audureau E; ELCAPA Study Group. Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version. The Oncologist 2016 Feb;21(2):188-95. doi: 10.1634/theoncologist.2015-0326
23. Petit-Monéger, M. Rainfray, P. Soubeyran, CA. Bellera, S. Mathoulin-Pélissier. Detection of frailty in elderly cancer patients: Improvement of the G8 screening test. J Ger Oncol 2016 Mar;7(2):99-107. pii: S1879-4068(16)00023-0. doi: 10.1016/j.jgo.2016.01.004.
24. Bron D, Soubeyran P, and Fulop T on behalf of the SWG “Aging and Hematology” of the EHA. Innovative approach of older patients with malignant hemopathies. Haematologica 2016 ; 101 (8) : 893-5. (Editorial). doi:10.3324/haematol.2016.142810
25. P Soubeyran, C Terret, C Bellera, F Bonnetain, O Saint Jean, A Galvin, C Chakiba, M-D Zwolakowski, S Mathoulin-Pélissier, M Rainfray. Role of geriatric intervention in the treatment of older patients with cancer: rationale and design of a phase III multicenter trial. BMC Cancer 2016;16(1):932. DOI: 10.1186/s12885-016-2927-4
26. Daste A, Chakiba C, Domblides C, Gross-Goupil M, Quivy A, Ravaud A, Soubeyran P. Targeted therapy and elderly people: A review. Eur J Cancer 2016 Dec;69:199-215. doi: 10.1016/j.ejca.2016.10.005. Review.
27. Kurtz JE, Soubeyran P, Michallet M, Luporsi E, Albrand H. Biosimilar Epoetin for the Management of Chemotherapy-Induced Anemia in Elderly Patients: A Subanalysis of the BiOsimilaRs in the management of anemia secondary to chemotherapy in HaEmatology and Oncology observational study (ORHEO). Oncotargets and Therapy 2016 Oct 28;9:6689-6693
28. S Duc, M Rainfray, P Soubeyran, M Fonck, JF Blanc, J Ceccaldi, L Cany, V.Brouste, S. Mathoulin-Pélissier. Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy. Psycho-Oncology 2016; 26(1):15-21. doi: 10.1002/pon.4090.
29. Ruella M and Soubeyran P. Ibrutinib in Mantle Cell Lymphoma of the Elderly. Hematology 2016 (1):432-436 (American Society of Hematology Educational Book 2016)
30. Soubeyran P, Gressin R. Treatment of the Elderly Patient with Mantle Cell Lymphoma. Hematology 2016(1):425-431 (American Society of Hematology Educational Book 2016)
31. F Kraeber-Bodere, A Pallardy, H Maisonneuve, L Campion, A Moreau, I Soubeyran, S  Le Gouill, O  Tournilhac, E  Daguindau, H  Jardel, N  Morineau, K  Bouabdallah, E Gyan; MP  Moles; R  Gressin, C  Berthou; S  Sadot, P  Moreau, B  Deau, C Bodet-Milin, AL  Cazeau, E Garin, PY  Salaun, JP  Vuillez,; WA Wegener; D M Goldenberg; T Lamy; P Soubeyran. Consolidation Anti-CD22 Fractionated Radioimmunotherapy with 90Y-Epratuzumab Tetraxetan Following R-CHOP in Elderly DLBCL Patients: A GOELAMS/LYSA Phase II Prospective Trial. The Lancet Haematology 2017; 4(1):e35-e45
32. CA Bellera, F Artaud, M Rainfray, PL Soubeyran, S Mathoulin-Pélissier. Modeling individual and relative accuracy of screening tools in geriatric oncology. Ann Oncol 2017 May 1;28(5):1152-1157. doi: 10.1093/annonc/mdx068.
33. Bron D, Aurer I, André MPE, Bonnet C, Caballero D, Falandry C, Kimby E, Soubeyran P, Zucca E, Bosly A, Coiffier B; European Lymphoma Institute (ELI) Group and the EHA SWG “Aging and Hematology”. Unmet needs in the scientific approach to older patients with lymphoma. Haematologica. 2017 Jun;102(6):972-975. doi: 10.3324/haematol.2017.167619
34. Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, De Mones E, Larmonier N, Soubeyran P, Ravaud A. Immune checkpoint inhibitors and elderly people : A review. Eur J Cancer 2017; 82: 155-66
35. Galvin A., Fleur Delva; Catherine Helmer; Muriel Rainfray; Carine Bellera; Virginie Rondeau; Pierre Soubeyran; Gaëlle Coureau; Simone Mathoulin-Pélissier. Sociodemographic, socioeconomic and clinical determinants of survival in cancer patients: a systematic review of the literature focused on the elderly. J Ger Oncol 2017, In Press
36. Bron D, Soubeyran P; EHA SWG on ‘Aging, Hematology’. Rational therapeutic choice for older patients with lymphoma. Curr Opin Oncol. 2017 Sep;29(5):322-327. doi: 10.1097/CCO.0000000000000394 In Press
37. Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trněný M, Wedding U, Fields P & the ESMO Lymphoma Consensus Conference Panel Members. ESMO Consensus Conference on malignant lymphoma : General perspectives and recommendations for the clinical management of elderly patients with malignant lymphoma. Ann Oncol 2018; 29(3): 544-62
38. Frasca M, Soubeyran P, Bellera C, Rainfray M, Leffondre K, Mathoulin-Pelissier S. Alterations in Comprehensive Geriatric Assessment decreases survival of elderly patients with cancer. Eur J Cancer 2018; 90:10-8. doi: 10.1016/j.ejca.2017.11.013
39. Galvin A, Delva F, Helmer C, Rainfray M, Bellera C, Rondeau V, Soubeyran P, Coureau G, Mathoulin-Pélissier S. Sociodemographic, socioeconomic and clinical determinants of survival in cancer patients: a systematic review of the literature focused on the elderly. J Ger Oncol 2018 Jan;9(1):6-14. doi:10.1016/j.jgo.2017.07.007
40. Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, Gressin R, Cornillon J, Banos A, Le Du K, Benchalal M, Moles MP, Le Gouill S, Fleury, Godmer P, Maisonneuve H, Deconinck E, Houot R, Laribi K, Marolleau JP, Colombat P, Branger B, Deviller A, Vuilliez JP, Fest T, Costes V, Szablewski V, Béné MC, Delwail V. R-CHOP 14 with or without Radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL): results of the prospective randomized phase III 02-03 trial from the LYSA/GOELAMS. Blood 2018;31(2):174-181. doi: 10.1182/blood-2017-07-793984
41. Falandry C, Krakowski I, Curé H, Carola E, Soubeyran P, Guérin O, Gaudin H, Freyer G. Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work. Breast Cancer Res Treat. 2018; 168(2): 433-41. doi: 10.1007/s10549-017-4607-8
42. Galvin A, Helmer C, Coureau G, Amadeo B, Joly P, Sabathé C, Monnereau A, Baldi I, Rainfray M, Soubeyran P, Delva F, Mathoulin-Pélissier S. Determinants of cancer treatment and mortality in older cancer patients using a multi-state model: Results from a population-based study (the INCAPAC study). Cancer Epidemiol. 2018 May 12;55:39-44
43. Tra-Ly Nguyen, Maxim Egorov, Clément Bodineau, Joanna Wdzieczak-Bakala, Maria Concepcion Garcia-Alvarez, Jerôme Bignon, Odile Thoison, Bernard Delpech, Georgiana Surpateanu, Yves-Michel Frapart, Fabienne Peyrot, Kahina Abbas, Silvia Terés, Pierre Soubeyran, Bogdan Iorga, Raul Duran, and Pascal Collin. A novel mechanism of mTOR inhibition displacing phosphatidic acid induces enhanced cytotoxicity specifically in cancer cells. Cancer Res 2018. In Press pii: canres.0232.2018. doi: 10.1158/0008-5472.CAN-18-0232
44. Elena Paillaud, Pierre Soubeyran, Philippe Caillet, Tristan Cudennec, Etienne Brain, Catherine Terret, Fanny Etchepare, Loïc Mourey, Thomas Aparicio, Frederic Pamoukdjian, Riccardo Audisio, Siri Rostoft, Arti Hurria, Carine Bellera, Simone Mathoulin-Pélissier, for the G-CODE collaborators. Multidisciplinary Development of a Geriatric COre DatasEt (G-CODE) for clinical research in older patients with cancer: a French initiative with international survey. Eur J Cancer 2018, In Press
45. Emmanuel Gyan, Anne Sonet, Pauline Brice, Bruno Anglaret, Kamel Laribi, Christophe Fruchart, Hervé Tilly, Carla Araujo, Pierre Soubeyran, Hugo Gonzalez, Nadine Morineau, Emmanuelle Nicolas‐Virelizier, Hervé Ghesquières, Bruno Salles, Réda Bouabdallah, Hubert Orfeuvre, Jonathan Fahri, Olivier Couturier, Luc Xerri, Pierre Feugier on behalf of the Lymphoma Study Association (LYSA). Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study. Br J Haematol In Press https://doi.org/10.1111/bjh.15513